Amgen reported strong first-quarter volume growth and raised its 2023 revenue and EPS guidance, reflecting confidence in its diverse product portfolio and strategic initiatives. Despite some sales declines in specific areas due to inventory adjustments, the overall positive outlook and managementâ€™s optimistic tone are likely to bolster investor sentiment in the short term.

[1]